Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Fineline Cube Jul 3, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Deals

Shanghai Operation Robot Secures RMB 100 Million Series C Funding for AI-Driven Surgical Robot Development

Fineline Cube Apr 22, 2025

Shanghai-based medical robotics developer Operation Robot Co., Ltd. has reportedly raised close to RMB 100...

Company Deals

Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management

Fineline Cube Apr 22, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...

Company Drug

Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction

Fineline Cube Apr 22, 2025

China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...

Company Medical Device

Broncus Medical Secures NMPA Approval for BroncAblate in Lung Cancer Treatment

Fineline Cube Apr 22, 2025

Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung disease, announced...

Company Drug

Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871

Fineline Cube Apr 22, 2025

Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received...

Company Deals

Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China

Fineline Cube Apr 22, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has entered into a hospital-channel...

Company Drug

HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial

Fineline Cube Apr 22, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment for the...

Company Drug

Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis

Fineline Cube Apr 21, 2025

China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...

Policy / Regulatory

Shanghai Healthcare Administration Pushes for 11th Round of VBP

Fineline Cube Apr 21, 2025

Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...

Company Medical Device

Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance

Fineline Cube Apr 21, 2025

Shenzhen-based minimally invasive laser medical device firm Vivolight Medical Device & Technology Co., Ltd has...

Company Drug

Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101

Fineline Cube Apr 21, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...

Company Drug

Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria

Fineline Cube Apr 21, 2025

France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...

Company Drug

Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China

Fineline Cube Apr 21, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that the Center for Drug Evaluation (CDE) in China...

Company Drug

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies

Fineline Cube Apr 21, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company Drug

Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine

Fineline Cube Apr 21, 2025

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the...

Company

Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs

Fineline Cube Apr 21, 2025

hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...

Company Deals

Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development

Fineline Cube Apr 21, 2025

China-based Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789), a state-owned integrated pharmaceutical company, has announced...

Company Drug

Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment

Fineline Cube Apr 21, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that its drug Gaoruizhe (golidocitinib) has received...

Company Drug

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 21, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical...

Company Medical Device

Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System

Fineline Cube Apr 21, 2025

US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...

Posts pagination

1 … 198 199 200 … 690

Recent updates

  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
  • Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery
  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Company

Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.